Market Newsdesk

JACKSONVILLE, Fla., July 14, 2026 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ:LSTR), announced today it will release its 2026 second quarter results after the market closes on Tuesday, July 28, 2026, and will then hold its quarterly conference call with analysts and investors at 4:30 p.m. ET that afternoon to discuss the second quarter results. To access the webcast, visit investor.landstar.com; click on “Webcasts”; and then “Landstar’s Second Quarter 2026 Earnings Release Conference Call.”

For those unable to participate in the live call, or for those who do not have access to the Internet, the call will be available on telephone replay for 48 hours. The telephone replay number for the U.S. and Canada is (800) 819-5743 and for international calls is (203) 369-3828.

About Landstar:

Landstar System, Inc., is a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation services to a broad range of customers utilizing a network of agents, third-party capacity providers and employees. Landstar transportation services companies are certified to ISO 9001:2015 quality management system standards and RC14001:2015 environmental, health, safety and security management system standards. Landstar System, Inc. is headquartered in Jacksonville, Florida. Its common stock trades on The NASDAQ Stock Market® under the symbol LSTR.

Contact: Jim Todd 
Landstar System, Inc.

904-398-9400

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026

Preclinical data for sutacimig in Factor VII deficiency (FVIID) demonstrate restoration of thrombin generation under disease-mimicking conditions and support its potential as a pan-hemostatic agent

Natural history studies in Glanzmann thrombasthenia (GT) confirm lifelong bleeding burden and critical underutilization of prophylaxis, underscoring the urgent need for preventive treatment

ISTH 2026 included nine total Hemab-led presentations delivering new clinical and preclinical data across sutacimig, HMB-002, and HMB-003

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 14, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. This follows the presentation of new clinical data from HMB-002 in Von Willebrand disease and the announcement of the HMB-003 program on Sunday, July 12.

“People living with GT and FVIID face a stark reality: no approved prophylaxis, a lifetime of unpredictable bleeds, and treatment options that have changed little in decades,” said Benny Sørensen, MD, PhD, CEO of Hemab. “The data we’ve presented at ISTH 2026 show how we’re closing that gap: sutacimig’s Phase 2 LTE results demonstrate sustained bleed reduction alongside a manageable safety and tolerability profile that has enabled FDA alignment on a Phase 3 dose and regimen. What underscores the relevance of these data is the real-world context supporting them. Natural history data from our GT360 and ATHN Transcends studies confirm that patients continue to bleed well into adulthood, prophylaxis remains critically underutilized, and the profound psychological toll—anxiety, isolation, diminished quality of life—extends far beyond bleed frequency.”

“The Phase 2 LTE data establish that sutacimig’s prophylactic benefit is durable, with a marked reduction in bleed events requiring high-intensity treatment and the first successful management of surgical cases on study,” said Quentin Van Thillo, MD, Department of Cardiovascular Diseases, Hemophilia Centre, University Hospitals Leuven, Belgium. “Together with natural history data documenting persistent bleeding burden and limited prophylaxis use, these findings support sutacimig’s advancement toward Phase 3 and the broader shift from reactive treatment to preventive care.”

Program Presentation

Sutacimig Phase 2 LTE data—reflecting treatment of 34 patients at a median of 6.9 months and up to 15.9 months of exposure—demonstrate a sustained prophylactic effect and reinforce the potential to shift people living with GT from reactive, IV-dependent treatment to subcutaneous prophylaxis, with regulatory alignment to proceed to Phase 3 with an agreed weekly regimen.

• Clinically meaningful annualized treated bleeding rate (ATBR) reduction: 92% of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig, and among participants who reported bleeding events that required transfusions, rFVIIa or hospitalization (high intensity bleeding events) within 12 months prior to receiving sutacimig, the mean high intensity annualized treated bleed event rate was reduced by 62% over the treatment and extension period. In all dose cohorts, the mean ATBR was reduced over the treatment and extension period, and in the low dose weekly regimen cohort, the mean ATBR was reduced by approximately 84%.
• First surgical use data: Three participants underwent procedures (two invasive surgeries and one dental procedure), all with successful hemostatic outcomes; one required a single post-procedure dose of recombinant Factor VIIa (rFVIIa).
• Safety: Adverse events were predominantly mild to moderate. There were no Grade 3 or higher related adverse events. Three participants experienced Grade 2 thromboembolic events. These occurred in participants assigned to dose cohorts associated with higher exposure and/or with multiple concurrent risk factors; all were managed with routine anticoagulation and were resolved or resolving at the datacut.
• Robust Phase 1/2 data: Enabled identification of a weekly Phase 3 dose with potential to optimize ATBR reduction while avoiding high peak exposures associated with TE in Phase 1/2. FDA has endorsed the clinical data package as sufficient to proceed to Phase 3 with a dose of 0.2mg/kg Q1 week.

Other Data Highlights

• Preclinical data for sutacimig in FVIID: Demonstrate restoration of thrombin generation under disease-mimicking conditions and support its potential across multiple indications, with retained binding expected for >90% of severe-to-moderate FVIID database variants and confirmed binding across 22 of 25 tested variants (88%), supporting broad patient applicability for the ongoing Phase 2 study.
• Lifelong GT bleeding burden (GT360, N=117): Over 90% of pediatric, adolescent, and young adult patients experience at least one bleed per week; 72% of those aged 40 and older still bleed weekly. Prevalence of depressive symptoms is 3-4x for the general population (32% vs. ~8–10%), with a stepwise relationship between bleeding frequency and psychological burden.
• Prophylaxis critically underutilized (ATHN Transcends, N=49): In 16.6 prospective patient-years of follow-up, mean ABR was 25.9 among participants experiencing bleeds and 44% of bleeds went untreated. Only 14% of patients received any prophylaxis.

About Glanzmann Thrombasthenia

Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients’ mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT.

About Factor VII Deficiency
Factor VII deficiency (FVIID) is a congenital severe bleeding disorder characterized by reduced levels of Factor VII, a naturally circulating blood coagulation protein. Patients with clinically severe FVIID suffer from recurrent, unpredictable, life-threatening or potentially disabling bleeding at critical sites, such as in the central nervous system, gastrointestinal tract and intra-articular locations, as well as recurrent mucocutaneous bleeds of the nose and gums with additional risks for female patients, consisting of heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage.

About Sutacimig (formerly HMB-001)

Sutacimig is a subcutaneously administered bispecific antibody that is designed to bind and stabilize endogenous Factor VIIa with one antibody arm and bind to TLT-1 on activated platelets with the other arm. This mechanism is designed to allow for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it amplifies thrombin generation at the platelet surface. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration has granted Fast Track Designation, Orphan Drug Designation, and Breakthrough Therapy Designation to sutacimig for the treatment of GT, and the UK Medicines and Healthcare products Regulatory Agency has awarded sutacimig designation under the Innovative Licensing and Access Pathway (ILAP); it has been designated as an orphan medicinal product in the European Union for the treatment of GT, and the European Medicines Agency (EMA) has granted sutacimig access to the Priority Medicines (PRIME) scheme. For more information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.‍

About HMB-002

HMB-002 is a monovalent human antibody being developed as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852)./

About HMB-003
HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an anti-fibrinolytic targeting plasmin inhibition in preclinical development for multiple high-unmet-need conditions, ranging from heavy menstrual bleeding, hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and first-in-human studies of HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab’s plans to expand its pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:

Deerfield Group
Peg Rusconi
[email protected]    

Investors:

Hemab Therapeutics
Mads Behrndt
[email protected]

VANCOUVER, British Columbia, July 14, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces it has signed new offers to acquire multiple land survey and geospatial services companies located in the US, Canada and Australia. Subject to the closing of these acquisitions, the Company expects them to collectively contribute approximately C$40 million in revenue over the 12 months following closing. This estimate is based on unaudited financial information provided by the target companies and by management estimates and has not been verified by auditors.

“These signed offers for acquisition mark a transformational milestone in building one of the world’s leading Drone as a Service businesses,” said Shaun Passley, Ph.D., ZenaTech CEO. “Beyond the expected addition of C$40 million in revenue over the first 12 months following closing, these potential acquisitions significantly expand our customer relationships, geographic reach, and geospatial expertise across three key markets. They create a scalable platform for integrating our AI-powered drone autonomy solutions into established operations, with the goal of accelerating recurring revenue opportunities while strengthening our competitive position. Building on our 640% year-over-year first quarter revenue growth, we believe this strategy positions ZenaTech for sustained long-term growth as enterprises and governments increasingly adopt drone-enabled services worldwide.”

These prospective transactions advance ZenaTech’s strategy of acquiring established legacy, and low-tech businesses, including land surveying, infrastructure and renewable energy inspections, and power washing companies in the U.S. and globally, and converting their traditional or manual operations to a Drone as a Service business model. The Drone as a Service (DaaS) model is similar to Software as a Service (SaaS), however instead of delivering software through a subscription, it delivers turnkey drone-powered services and data on a recurring subscription or usage basis. Customers gain access to advanced surveying, inspection, monitoring, precision agriculture and other drone-enabled capabilities without the upfront capital investment, specialized personnel, equipment maintenance, or regulatory complexity of operating their own drone fleet.

The global drone services market is valued at approximately US$32 billion in 2025 according to Fortune Business Insights, and is projected to reach more than US$261 billion by 2034, a CAGR of over 25% which reflects the rapid adoption of drone automation across infrastructure inspection, surveying, agriculture, logistics, public safety, and defense applications

Each proposed acquisition remains subject to customary closing conditions, including the completion of due diligence and signed definitive agreements. There can be no assurance that any proposed transaction will be completed. The Company will provide additional details upon the closing of such transactions.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform industrial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and a separate enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, and Asia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media:

Linda Montgomery

ZenaTech

312-241-1415

[email protected]

Investors:

Michael Mason

CORE IR

[email protected]

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.  Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square, IQ Aqua, IQ Sphere, IQ Nano, and counter UAS interceptor drones; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎

WINNIPEG, Manitoba, July 14, 2026 (GLOBE NEWSWIRE) — Frontier Nuclear and Minerals Inc. (Nasdaq:FNUC) (“Frontier”), a nuclear fuel cycle company, announces the launch of its 2026 drill program at its 100% owned Pine Ridge uranium project (“Pine Ridge”) in Wyoming’s Powder River Basin.

A 36,000 m Drill Program designed to generate



a maiden mineral resource estimate

Highlights

• 2026 drill program (the “Drill Program”) at Pine Ridge is underway
• Drill program will consist of approximately 120 holes totaling approximately 36,000 m
• Drill Program will build on the successful 2025 drill program which:
  • confirmed widespread uranium mineralization;
  • demonstrated continuity of mineralization across multiple areas; and
  • identified at least 25 mineralized roll fronts contained within multiple major sandstone packages.
• Objective of the Drill Program is to define roll front deposits and target preparation of a maiden mineral resource estimate (the “MRE”) by early 2027
• Pine Ridge is a large-scale uranium exploration project located in Wyoming’s prolific Powder River Basin covering approximately 39,390 acres

CEO Commentary

“After a successful initial drill campaign during 2025, we have initiated an extensive 2026 drill program at Pine Ridge,” said Frank Wheatley, CEO of Frontier. “The clear objective of this program is to complete sufficient drilling to prepare a maiden mineral resource estimate by early 2027.”

“As the U.S. Government continues to prioritize development of a domestic nuclear fuel cycle, the U.S. needs to develop additional uranium mines in order to achieve its target of energy security through nuclear power. We believe Pine Ridge holds the potential to positively contribute to that goal,” continued Mr. Wheatley.

2026 Pine Ridge Drill Program

The Drill Program will include nearly 120 drill holes totaling approximately 36,000 meters. Drilling is expected to be completed using one drill rig operating from July through December 2026, with the program potentially extending into January 2027.

The Drill Program will build on the successful 2025 drill program which confirmed widespread uranium mineralization, demonstrated continuity of mineralization across multiple areas, and identified at least 25 mineralized roll fronts contained within multiple major sandstone packages.

Figure 1: Pine Ridge Uranium Project

Frontier’s geology team has integrated the results of the 2025 drill program with Pine Ridge’s extensive historical drilling and geophysical database to refine the geological model and prioritize targets for the Drill Program. The Drill Program is designed to expand and further define priority mineralized trends, test additional prospective sandstone horizons, and advance Pine Ridge toward the definition of a maiden mineral resource estimate.

Results from the 2025 drill program illustrate the continuity of the stacked roll-front systems identified across Pine Ridge and confirm mineralized zones within multiple major sandstone packages in the eastern and southwestern portions of Pine Ridge. These mineralized zones generally occur at depths of approximately 200 meters to 400 meters and are separated by laterally extensive fine-grained units that provide geological and hydrological confinement, supporting Pine Ridge’s potential suitability for future In-Situ Recovery development.

Importantly, mineralization intersected in the southwestern portion of Pine Ridge appears to be hosted within a stratigraphically lower sandstone package than the mineralized sandstone packages identified in the eastern portion of Pine Ridge. This interpretation suggests that additional prospective areas and sandstone horizons may be present across Pine Ridge.

In conjunction with preparations for the 2026 exploration program, Frontier expanded the Pine Ridge claim block through the addition of 54 federal mining claims, comprising approximately 854 acres.

Pine Ridge Uranium Project

Pine Ridge is an advanced In-Situ Recovery (“ISR”) uranium exploration project located in the southwestern Powder River Basin of Wyoming, the premier uranium-producing basin in the United States.

Pine Ridge is surrounded by existing uranium projects held by established uranium operators and explorers. It is located approximately 15 kilometers from Cameco’s Smith Ranch processing facility, which has a licensed capacity of 5.5 million pounds of U₃O₈ p.a. Smith Ranch mill is one of the largest uranium production facilities in the United States.

Pine Ridge benefits from an extensive historical exploration database comprising 1,311 historical drill holes totaling more than 22,825 meters of drilling, supplemented by 114 drill holes totaling 38,000 meters completed by Frontier during the 2025 exploration program. This combined dataset provides the foundation for Pine Ridge’s geological interpretation and the targeting of the Drill Program.

Wyoming Uranium Mining Industry

The Pine Ridge Uranium Project is located in the southwestern Powder River Basin of Wyoming, the premier U.S. uranium basin. Historically, the Powder River Basin is the most significant area for uranium production in U.S. primarily via ISR production methods, and Wyoming has produced nearly 240 Mlbs U₃O₈ since 1951.

ISR uranium mining offers significant advantages over conventional hard rock mining, particularly in terms of environmental impact and cost efficiency. ISR requires no large-scale open pits or underground tunnels, minimizing surface disturbance and eliminating the need for waste rock and tailings storage. This translates to a much lower environmental footprint, reduced water usage, and streamlined permitting processes. Additionally, ISR operations typically have lower capital expenditures and operating costs due to their simpler infrastructure requirements and more efficient extraction methods.

About Frontier Nuclear and Minerals Inc.

Frontier Nuclear and Minerals Inc. is focused on building a U.S.-based nuclear fuel cycle platform through uranium exploration and development assets, together with targeted investments in Ubaryon Pty. Ltd., a private Australian company developing next generation enrichment technology, and Kadmos Energy Services LLC, a private U.S. company developing small modular light water reactors. Frontier continues to evaluate opportunities in the nuclear fuel cycle that align with its long-term strategic objectives.

For more information, visit: www.frontiernuclear.com

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including without limitation statements with regard to Frontier Nuclear and Minerals Inc., the timing and outcome of drilling and any maiden mineral resource estimate for the Pine Ridge uranium project, the future of the Pine Ridge uranium project, anticipated uranium demand, U.S. federal nuclear policy and funding initiatives, and Frontier Nuclear and Minerals Inc.’s strategic positioning. References to third-party statements, including industry estimates of future uranium demand and statements made by government agencies, are included for context and are not adopted by Frontier Nuclear and Minerals Inc. as projections of its own results. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Frontier Nuclear and Minerals Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Some of these risks and uncertainties are described more fully in the section titled “Risk Factors” in our registration statements and annual reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Frontier Nuclear and Minerals Inc. undertakes no duty to update such information except as required under applicable law.

For Further Information:

Frank Wheatley	Investor Relations
Chief Executive Officer	[email protected]
[email protected]	www.frontiernuclear.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1d47d2f-fb6d-4f6d-bdac-85d2c56956ed

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today highlighted the recent update to the National Comprehensive Cancer Network^® (NCCN^®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer.

The updated NCCN CNS Cancers Guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI and clinical evaluation.

CNSide is a CSF assay platform designed to support the diagnosis, treatment monitoring, and management of patients with LM and other metastatic central nervous system cancers. The Company believes the updated NCCN framework underscores the value of more sensitive and quantitative CSF-based tools that can operate within existing clinical workflows and complement standard CSF cytology over the course of a patient’s treatment.

“A quantitative assay such as CNSide Tumor Cell Enumeration can complement standard cytology by detecting disease more sensitively and by enabling longitudinal monitoring of tumor burden over time,” said Michael Youssef, M.D., neuro-oncologist at Houston Methodist. “For neuro-oncologists managing patients with leptomeningeal disease, that combination of higher sensitivity and serial quantitative assessment can be clinically very meaningful.”

Recent publicly presented CNSide data suggest the platform may provide materially greater sensitivity than conventional cytology in matched CSF samples while also providing quantitative tumor-cell information that may influence patient management. In data presented from the FORESEE study, investigators reported that compared with cytology in matched samples, CNSide more than doubled the sensitivity of tumor detection in patients with LM. The Company has also previously described CNSide as a quantitative CSF assay platform intended to support rapid diagnosis, treatment monitoring, and treatment guidance in metastatic CNS cancers.

The NCCN update also reflects the growing role of CSF-based molecular testing across CNS cancers, including expanded recommendations in certain biopsy-infeasible high-grade gliomas and glioblastoma settings. The Company believes this broader recognition of CSF-based diagnostics supports long-term strategic interest in integrated CSF testing approaches that combine tumor-cell analysis with molecular characterization from a single patient specimen.

Leptomeningeal metastases occur in an estimated 5% to 10% of patients with cancer and are associated with substantial morbidity, complex clinical management, and significant healthcare utilization. The Company previously announced health economics data indicating that use of the CNSide platform may reduce LM-related healthcare costs by approximately 40%, highlighting the potential economic importance of earlier and more confident diagnostic and patient management decisions.

CNSide has continued to expand its U.S. commercial foundation in 2026, including Medicare enrollment approval, CAP accreditation, and payer coverage expansion with Blue Shield of California and Elevance Health. Following the Elevance agreement, CNSide reported total contracted coverage of approximately 126 million covered lives in the United States. The Company has stated a 2026 objective of 150 million covered lives and 1,250 total CNSide tests performed.

The Company also expects CNSide clinical and commercial visibility to benefit from upcoming scientific presentations and continued engagement with neuro-oncology thought leaders active in LM care and research. The Company believes these activities can further support physician awareness of CSF-based longitudinal monitoring approaches in this underserved area of oncology.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc., develops and commercializes proprietary laboratory-developed tests such as CNSide^®, which is designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide^® CSF Assay Platform enables quantitative analysis of cerebrospinal fluid to inform and improve the management of patients with leptomeningeal metastases. For more information, please visit www.cnside-dx.com.

About Plus Therapeutics

Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage healthcare company advancing an integrated approach to central nervous system (CNS) cancers through precision therapeutics, molecular diagnostics and data-driven technologies. The Company’s lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being developed for the treatment of leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers. Its CNSide^® cerebrospinal fluid assay platform is designed to provide diagnostic and disease monitoring information to support the management of patients with CNS cancers. Together with its growing data and artificial intelligence capabilities, Plus Therapeutics is building an integrated CNS oncology platform intended to improve clinical decision-making, accelerate therapeutic development and advance personalized care for patients with CNS cancers.

Effective August 3, 2026, Plus Therapeutics will change its corporate name to Cerenome, Inc. and begin trading under the Nasdaq ticker symbol CNSY. Until that date, the Company will continue to operate as Plus Therapeutics and trade under the ticker symbol PSTV.

For more information, please visit www.plustherapeutics.com. Beginning August 3, 2026, additional information will be available at www.cerenome.com.

Disclaimer

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References to NCCN Guidelines describe publicly available clinical context and do not imply endorsement by NCCN of any specific commercial product.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact

CORE IR
[email protected]

ROGERS, Ark., July 14, 2026 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the fourth quarter and full year ended April 30, 2026.

Full Year Key Results (FY’26 vs. FY’25, unless otherwise noted)

• Total revenue of $1,281.5 million, down 7.9%; interest income increased 3.7% to $253.7 million
• Sales volumes declined 14.3% to 48,891 units, reflecting reductions in both the active dealership base and inventory purchases, partially offset by a 3.4% increase in the average retail sales price
• Gross profit per unit improved 1.0% to $7,442; gross margin percentage of 35.4% vs. 36.7%
• Total collections of $730.0 million, up 2.2% year-over-year
• Net charge-offs as a percentage of average finance receivables were 27.6% vs. 25.9%
• SG&A of $208.1 million; includes $4.0 million in non-recurring restructuring-related charges; adjusted SG&A^[¹^] of $204.1 million, or 19.9% of sales
• Non-cash impairment of $11.0 million related to the dealership consolidations, reported on a separate line from SG&A
• Loss per share of $16.79 and adjusted loss per share^[1] of $3.71
  ^[1]Calculation of this non-GAAP financial measure and a reconciliation to the most directly comparable GAAP measure are included in the tables accompanying this release.

President and CEO Doug Campbell commentary: 

Our fourth quarter results reflect the actions we took to preserve liquidity, reduce risk, and operate within our capital structure — and you can see that in our financial performance. The year did not meet our expectations, but this is a liquidity and capital-structure story, not a credit-quality one.

On credit, our charge-off ratio ticked up to 7.5% in the fourth quarter, from 6.9% a year ago. Part of that is simply a smaller book — with fewer new loans, our finance receivables are about 6.4% smaller than a year ago, and a smaller balance raises the percentage. The rest reflects our customers paying more at the pump for much of the year, along with some disruption from our dealership consolidations — and we’re watching both closely. Underlying credit behavior has been relatively stable, even against those pressures.

With respect to our dealership consolidations, the customer accounts from our closed stores moved to stronger nearby locations, or to a centralized collections team we built for the first time earlier this year — a way to serve accounts where the nearest store was no longer a practical fit. That was the right call for the business. It was also a hard one for the associates affected, and I don’t want that to get lost in the numbers. We’ve worked to handle it the right way, with severance pay and assistance in helping those associates find their next role.

On June 19, 2026, we amended our credit agreement with our senior secured term loan lenders. The amendment gives us covenant relief and a defined window to complete our previously disclosed review of strategic and financing alternatives. It also sets specific milestones we are required to satisfy and meeting them is central to the path forward. You’ll also see a going-concern disclosure in our Form 10-K. It’s because we have not yet secured the additional financing or alternative transaction needed to resolve our liquidity constraint. An independent review is underway to assess a wide range of alternatives to get this right for the people who depend on us: our creditors, shareholders, customers, vendors, and associates.

To our customers: our job every day is still to keep you on the road, and that continues without interruption. To our vendors and associates: I know there are a lot of questions right now, and I’m not going to pretend otherwise. It takes what it takes to work through this the right way, and that’s where our focus is. To our shareholders: I know this has been a difficult and uncertain period, and you have every right to expect us to work through it with urgency and discipline. That is exactly what this team and this Board are doing. Thank you for staying with us through a hard year. We do not take it for granted.

Fiscal year 2026 Key Operating Metrics

Dollars in thousands, except per share data. Dollar and percentage changes may not recalculate due to rounding. Charts may not be to scale.

Fourth Quarter Business Review

Note: Discussions in each section provide information for the fourth quarter of fiscal year 2026, compared to the fourth quarter of fiscal year 2025, unless otherwise noted.

SALES VOLUME – Retail units sold decreased 27.1% to 11,411 units when compared to the prior year’s quarter. These results were driven primarily by lower inventory levels — the result of the reduced availability of origination capital and reduced inventory purchases to preserve capital — and, to a lesser extent, the earlier store consolidations completed in the third quarter.

Sales volumes during the quarter are not indicative of underlying consumer demand. Lead indicators for demand remained robust throughout the quarter.

TOTAL REVENUE – Total revenue for the quarter was $302.8 million, a decrease of 18.2% year-over-year. The decline was driven by lower retail unit volume — consistent with the reduction in inventory purchases and the earlier store consolidations discussed above — partially offset by a 5.7% increase in the average retail sales price to $20,138. Interest income was largely stable, decreasing 0.5% to $60.2 million.

GROSS PROFIT – Gross profit margin as a percentage of sales was 31.2%, compared to 36.4% in the prior year quarter. Total gross profit per retail unit sold decreased by 8.1% to $6,627. Most of the decline reflected lower origination volume, which reduced the share of higher-margin retail sales relative to wholesale volume, as well as fixed charges within cost of sales that do not scale down with lower sales volume.

SG&A EXPENSE – SG&A expenses totaled $47.6 million for the quarter, or 19.6% of sales, compared to $48.3 million and 15.6% of sales in the prior year quarter. The current quarter included approximately $4.0 million in non-recurring restructuring charges related primarily to our capital structure strategic review. Excluding these items, adjusted SG&A (non-GAAP¹) was $43.6 million, or 18.0% of sales.

The Company continued to make progress on its footprint optimization initiative. During the quarter, the Company consolidated 42 dealership locations into nearby, higher-performing dealerships, and consolidated some customer accounts into a centralized collections team. Including the Company’s Q3 reductions in footprint, this reduced the Company’s active dealership count from 154 at April 30, 2025 to 94 at April 30, 2026. The Company remains committed to adjusting its SG&A to match anticipated sales volumes.

IMPAIRMENT – The Company recognized $6.4 million of non-cash impairment during the quarter and $11.0 million for the full year, related to long-lived assets at the dealership locations consolidated during fiscal 2026. These charges are reported on a separate line from SG&A and have no impact on cash flow or liquidity.

CREDIT AND UNDERWRITING PERFORMANCE – Net charge-offs as a percentage of average finance receivables were 7.5%, compared to 6.9% in the prior year quarter. The increase in the ratio partly reflects the contraction in the receivables base — the principal balance of finance receivables declined 6.4% compared to the prior year quarter as management moderated originations due to liquidity constraints. Adjusting for that smaller base, net charge-offs would have been lower, with only a modest increase related to continued fuel and cost-of-living pressure on the Company’s customers, and not to any change in underwriting standards.

Total collections were $185.7 million, down 2.8% from the prior year quarter, reflecting the smaller receivables base; average collected per active customer per month improved to $617 from $612, aided by the Company’s Pay Your Way digital payment platform, through which approximately 64% of payment transactions are now processed remotely.

Accounts over 30 days past due were 4.1% at year-end, up from 3.4% a year ago but down sequentially from 4.4% at January 31, 2026. The sequential improvement is notable, as the fourth quarter absorbed additional store closures that would ordinarily push delinquencies higher, while the January 31 reading was itself elevated by Winter Storm Fern and the third-quarter store closures. The year-end measure was further affected by the timing of the April closures — when accounts were being moved to nearby stores and to the centralized collections team — and by the smaller receivables base against which delinquency is calculated.

Car-Mart’s disciplined underwriting approach continues to strengthen its receivables portfolio, with the highest credit-tier customers now representing 66.6% of accounts receivable, up from 64.6% in the prior year quarter.

ALLOWANCE FOR CREDIT LOSSES – The allowance for credit losses was $329.9 million at April 30, 2026, or 25.15% of finance receivables, net of deferred revenue and pending accident protection plan claims, compared to 23.25% at April 30, 2025 and 25.53% at January 31, 2026.

The year-over-year increase primarily reflects the broader macroeconomic environment, rather than a change in underlying credit behavior, and the reduction in finance receivable originations undertaken to preserve liquidity. These effects were partially offset by portfolio mix shifts, including the growing share of receivables originated under our loan origination system (LOS) and those added through dealership locations acquired during fiscal year 2025. The modest sequential decline from January 31 reflects the contraction in the receivables base and stable underlying credit trends. Management considers the allowance adequate to reflect the risk profile of the portfolio at April 30, 2026.

LEVERAGE & LIQUIDITY – Total debt declined to $722.4 million, a reduction of $54.4 million, or 7.0%, from $776.8 million at April 30, 2025. Total debt, net of cash (non-GAAP¹), declined to $590.7 million, a reduction of $61.5 million, or 9.4%, from $652.2 million at April 30, 2025. Debt to finance receivables was 51.1% at April 30, 2026, compared to 51.5% at April 30, 2025. Net debt to finance receivables (non-GAAP¹) was 41.8% at April 30, 2026, the lowest level in three years — since April 30, 2023.

Total cash, including restricted cash, increased to $131.6 million at April 30, 2026, compared to $124.5 million at April 30, 2025. Unrestricted cash, which is available to fund operations and capital needs, was $47.0 million at April 30, 2026, up from $9.8 million a year earlier under the Company’s prior asset-based facility. Absent a revolving credit facility, preserving unrestricted liquidity remains a primary focus. The Company has taken deliberate steps to align its cost structure with available capital, including the store footprint rationalization discussed earlier. Total debt decreased to $722.4 million from $776.8 million at April 30, 2025, and total debt, net of total cash, (non-GAAP¹) decreased to $590.7 million from $652.2 million at April 30, 2025.

CAPITAL STRUCTURE – On June 19, 2026, we entered into an amendment to our Credit and Guaranty Agreement with our lending group, which provides covenant relief and a defined runway that will give the Company – with the guidance of the Special Committee – time to evaluate a full range of financing and strategic options available. As of the June 30, 2026 testing date under the amendment, the Company was in compliance with all applicable covenants, and it remains in compliance as of the date of this release. We view the amendment as a constructive step in improving our capital structure, reflecting our lenders’ continued engagement while also giving us the time to fully review the strategic alternatives available. The Company remains focused on the interests of its lenders, shareholders, associates, customers, and vendors as it evaluates the alternatives available.

The Company’s work ahead is focused on translating asset value into a sustainable funding restructure, either through a warehouse facility, a recapitalization, or another financing transaction, and the amendment gives the Company the time to pursue that in an orderly and thoughtful manner. Securing an additional readily available financing source, such as a revolving warehouse facility or other potential debt facility, remains the critical next step in restoring origination capacity and would provide bridge financing between origination and securitization that allows the Company to fully serve customer demand and restore sales volume. The Company cannot assure, however, that it will be able to secure any such financing on acceptable terms, or at all, or that the review of strategic and financing alternatives will result in any transaction or other outcome favorable to the Company or its stockholders.

GOING CONCERN – In accordance with ASC 205-40, the Company’s substantial indebtedness, its liquidity position, and the uncertainties associated with satisfying the milestones under the amendment to its Credit and Guaranty Agreement and securing additional financing raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. Management’s plans to address these conditions have not been fully implemented and do not alleviate that doubt. The financial statements have been prepared on a going-concern basis and include no related adjustments. See Note B (Liquidity and Going Concern) in the Company’s Form 10-K.

INTEREST EXPENSE – Interest expense for the quarter was $20.0 million, an increase of $2.6 million, or 15.1%, compared to $17.4 million in the prior year quarter. The increase reflects the full-quarter impact of the $300 million term loan closed in October 2025 and the December 2025 asset-backed securitization (ABS) transaction. Subject to the attainment of additional financing to support the Company’s operations, the Company’s transition to residual ABS structures and continued capital structure refinements are expected to improve the Company’s cost of funds over time.

INCOME TAXES – In fiscal 2026, the Company recorded an income tax provision of $31.1 million for the full year, an effective rate of (28.8)%, despite a pre-tax loss for the year. The provision was driven principally by the non-cash valuation allowance established in the third quarter against the deferred tax asset associated with net operating losses at Colonial Auto Finance.

¹
_{The calculation of this non-GAAP financial measure and a reconciliation to the most directly comparable GAAP measure are included in the tables accompanying this release.}

Key Operating Results
	Three Months Ended
	April 30,
		2026					2025				Change
Operating Data:
Retail units sold		11,411					15,649				(27.1	)	%
Average number of dealerships in operation		128					154				(16.9	)	%
Average retail units sold per dealerships per month		29.7					33.9				(12.4	)	%
Average retail sales price	$	20,138				$	19,049				5.7		%
Total gross profit per retail unit sold	$	6,627				$	7,209				(8.1	)	%
Total gross profit percentage		31.2		%			36.4		%		(520	)	bps
Same dealership revenue growth		(6.1	)	%			(3.9	)	%
Net charge-offs as a percent of average finance receivables		7.5		%			6.9		%		60		bps
Total collected (principal, interest and late fees), in thousands	$	185,710				$	191,114				(2.8	)	%
Average total collected per active customer per month	$	617				$	612				0.8		%
Average percentage of finance receivables-current (excl. 1-2 day)		73.2		%			80.2		%		(700	)	bps
Average down-payment percentage		6.1		%			6.2		%		(10	)	bps
	Twelve Months Ended
	April 30,
		2026					2025				Change
Operating Data:
Retail units sold		48,891					57,022				(14.3	)	%
Average number of dealerships in operation		146					154				(5.2	)	%
Average retail units sold per dealerships per month		27.9					30.9				(9.7	)	%
Average retail sales price	$	20,064				$	19,398				3.4		%
Total gross profit per retail unit sold	$	7,442				$	7,368				1.0		%
Total gross profit percentage		35.4		%			36.7		%		(130	)	bps
Same dealership revenue growth		(2.2	)	%			(5.0	)	%
Net charge-offs as a percent of average finance receivables		27.6		%			25.9		%		170		bps
Total collected (principal, interest and late fees), in thousands	$	730,048				$	714,102				2.2		%
Average total collected per active customer per month	$	591				$	575				2.7		%
Average percentage of finance receivables-current (excl. 1-2 day)		76.3		%			81.4		%		(510	)	bps
Average down-payment percentage		5.1		%			5.5		%		(40	)	bps
Period End Data:
Dealerships open		94					154				(39.0	)	%
Accounts over 30 days past due		4.1		%			3.4		%
Active customer count		97,696					104,682				(6.7	)
Principal balance of finance receivables (in thousands)	$	1,413,059				$	1,509,154				(6.4	)
Weighted average total contract term		49.0					48.3				1.4

Conference Call and Webcast

The Company will hold a conference call to discuss its quarterly results on Tuesday, July 14, 2026, at 9:00 a.m. ET. Participants may access the conference call via webcast using this link: Webcast Link. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial in 10 minutes prior to the start time. A replay and transcript of the conference call and webcast and related supplemental information will be available on-demand via the Company’s investor relations webpage at ir.car-mart.com for 12 months from July 14, 2026.

About America’s Car-Mart, Inc.

America’s Car-Mart, Inc. (the “Company”) operates automotive dealerships in 12 states and is one of the largest publicly held automotive retailers in the United States focused exclusively on the “Integrated Auto Sales and Finance” segment of the used car market. The Company emphasizes superior customer service and the building of strong personal relationships with its customers. The Company operates its dealerships primarily in smaller cities throughout the South-Central United States, selling quality used vehicles and providing financing for substantially all of its customers. For more information about America’s Car-Mart, including investor presentations, please visit our website at www.car-mart.com.

Non-GAAP Financial Measures

This news release contains financial information determined by methods other than in accordance with generally accepted accounting principles (GAAP). Specifically, we present as non-GAAP financial measures in this news release adjusted SG&A as a percentage of sales; adjusted earnings (loss) per share; total debt, net of total cash; and the ratio of debt, net of cash, to finance receivables. These non-GAAP measures are provided as supplemental measures to evaluate operating performance, cost structure, and leverage, and portfolio economics and to facilitate period-to-period comparisons that may be impacted by non-recurring or non-cash items. We believe investors benefit from referring to these non-GAAP measures and ratios in assessing our leverage, balance sheet risk, operating results and related trends, and when planning and forecasting future periods.

These measures should not be considered in isolation or as substitutes for reported GAAP results, as they may include or exclude certain items relative to similar GAAP-based measures and may not be comparable to similarly titled measures reported by other companies. We strongly encourage investors to review our consolidated financial statements included in our publicly filed reports in their entirety and not rely solely on any one financial measure or communication. The most directly comparable GAAP financial measures, as well as reconciliations to those measures, are presented in the tables accompanying this release.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements address the Company’s future events, objectives, plans and goals, as well as the Company’s intent, beliefs and current expectations and projections regarding future financial and operating performance and can generally be identified by words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “intend,” “plan,” “project,” “foresee,” and other similar words or phrases. Specific events addressed by these forward-looking statements may include, but are not limited to:

• the Company’s ability to continue as a going concern;
• the Company’s review of strategic and financing alternatives and the potential outcomes of that review;
• the covenant relief and waivers under, and the Company’s ability to satisfy the milestones and other conditions of, the June 19, 2026 amendment to the Company’s Credit and Guaranty Agreement;
• the Company’s liquidity and its efforts to preserve liquidity, including the curtailment of inventory purchases and finance receivable originations;
• future earnings performance;
• the availability of capital, including through income from operations and securing additional financing to sustain and supplement operating cash flows through additional securitization transactions, warehouse credit facilities, or other sources, and the Company’s ability to consummate such financing transactions;
• the benefits of recent or future changes to the Company’s capital structure;
• operational infrastructure investments;
• technological investments and initiatives;
• the impact of cost reduction and dealership footprint optimization initiatives on operating performance and customer service levels;
• the Company’s ability to execute its business plan; and
• the Company’s business, operating and growth strategies and expectations.

These forward-looking statements are based on the Company’s current estimates and assumptions and involve various risks and uncertainties. As a result, you are cautioned that these forward-looking statements are not guarantees of future performance, and that actual results and events could differ materially from those projected in these forward-looking statements. Factors that may cause actual results or events to differ materially from the Company’s projections include, but are not limited to:

• the existence of substantial doubt about the Company’s ability to continue as a going concern, and the effects of that disclosure on the Company’s relationships with customers, associates, suppliers, lenders and other stakeholders;
• the Company’s ability to satisfy the milestones and other conditions of the June 19, 2026 amendment to its Credit and Guaranty Agreement, to extend the related covenant relief and waiver period, and to obtain further waivers, covenant relief, forbearance or financing from its lenders on acceptable terms, or at all;
• the outcome of the Company’s review of strategic and financing alternatives, including the risk that the review does not result in any transaction, results in a transaction on unfavorable terms, or is not completed in a timely manner, and the costs, timing and uncertainties associated with the review and related advisory engagements;
• the Company’s substantial level of indebtedness and its ability to service that indebtedness, and the risk that its indebtedness could be accelerated (including under cross-default or cross-acceleration provisions) and that the Company would not have sufficient liquidity to repay it;
• the Company’s ability to fund finance receivable originations, vehicle inventory purchases, debt service and operating expenses, including its ability to establish a warehouse credit facility and to continue to complete asset-backed securitization transactions;
• the curtailment of the Company’s vehicle inventory purchases and finance receivable originations and the effect of that curtailment on the Company’s sales, revenues and collections;
• the Company’s changes to customer collection practices, including the transition to a centralized collections model and the transfer of customer accounts to dealerships located farther from customers’ prior collection locations and the effect of the change on collections, revenues, and customer relationships;
• the potential need for the Company to seek protection under applicable bankruptcy or insolvency laws;
• the possibility that holders of the Company’s common stock could experience a significant or complete loss of their investment, including as a result of any restructuring, recapitalization, or dilutive issuance of equity or equity-linked securities;
• the Company’s ability to maintain compliance with the continued listing requirements of, and the continued listing of its common stock on, the Nasdaq Stock Market;
• the diversion of management’s attention from ordinary-course operations as a result of the strategic review and the Company’s liquidity and capital-structure matters;
• general economic conditions in the markets in which the Company operates, including but not limited to fluctuations in gas prices, grocery prices and employment levels and inflationary pressure on operating costs;
• the availability of quality used vehicles at prices that will be affordable to the Company’s customers, including the impacts of changes in new vehicle production and sales;
• the availability of and access to capital through warehouse credit facilities, securitization financings or other debt or equity financing on terms acceptable to the Company, and any increase in the cost of capital, to support the Company’s business;
• the Company’s ability to consummate debt or equity financing transactions on terms acceptable to the Company;
• the Company’s compliance with financial covenants and other terms of its senior secured term loan, non-recourse notes payable, and any future debt facilities;
• the Company’s ability to underwrite and collect its contracts effectively, including whether anticipated benefits from the Company’s recently implemented loan origination system are achieved as expected or at all;
• competition;
• dependence on existing management;
• ability to attract, develop, and retain qualified general managers;
• changes in consumer finance laws or regulations, including but not limited to rules and regulations that have recently been enacted or could be enacted by federal and state governments;
• future shutdowns of the federal government or changes to federal or state government assistance programs impacting the Company’s customers;
• the ability to keep pace with technological advances and changes in consumer behavior affecting our business;
• security breaches, cyber-attacks, or fraudulent activity;
• the ability to identify and obtain favorable locations for new or relocated dealerships at reasonable cost;
• the ability to successfully transition customers and inventory from underperforming dealerships to nearby more productive dealerships as part of the Company’s footprint optimization strategy;
• the ability to successfully identify, complete and integrate new acquisitions;
• the occurrence and impact of any adverse weather events or other natural disasters affecting the Company’s dealerships or customers;
• the Company’s ability to maintain effective internal control over financial reporting following the remediation of its previously identified material weakness, and to design, implement, and maintain effective disclosure controls and procedures;
• the potential dilutive impact of outstanding warrants to purchase the Company’s common stock, if exercised, and of any other future issuances of the Company’s equity securities; and
• potential business and economic disruptions and uncertainty that may result from any future public health crises and any efforts to mitigate the financial impact and health risks associated with such developments.

Additionally, risks and uncertainties that may affect future results include those described from time to time in the Company’s SEC filings. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

Jonathan Collins
Chief Financial Officer
(479) 464-9944
[email protected]

SM Berger & Company
Andrew Berger, Managing Director
[email protected]
(216) 464-6400

Media Contact
Rachel Chesley / Misha Ross
[email protected]

America’s Car-Mart
Consolidated Results of Operations
(Amounts in thousands, except per share data)
													As a % of Sales
		Three Months Ended											Three Months Ended
		April 30,											April 30,
			2026				2025			% Change			2026			2025
Statements of Operations:
Revenues:
Sales		$	242,637			$	309,702			(21.7	)	%	100.0		%	100.0	%
Interest income			60,189				60,472			(0.5	)		24.8			19.5
Total			302,826				370,174			(18.2	)		124.8			119.5
Costs and expenses:
Cost of sales			167,022				196,896			(15.2	)		68.8			63.6
Selling, general and administrative			47,565				48,343			(1.6	)		19.6			15.6
Provision for credit losses			91,914				92,962			(1.1	)		37.9			30.0
Interest expense			19,993				17,373			15.1			8.2			5.6
Impairment expense			6,382				–			–			2.6			–
Depreciation and amortization			1,926				1,947			(1.1	)		0.8			0.6
(Gain) loss on disposal of property and equipment			(235	)			175			(234.3	)		(0.1	)		0.1
Total			334,567				357,696			(6.5	)		137.9			115.5
Income (Loss) before taxes			(31,741	)			12,478						(13.1	)		4.0
Provision (benefit) for income taxes			(2,176	)			1,843						(0.9	)		0.6
Net income (loss)		$	(29,565	)		$	10,635						(12.2	)		3.4
Dividends on subsidiary preferred stock			(10	)			(10	)
Net income (loss) attributable to common shareholders		$	(29,575	)		$	10,625
Earnings (Loss) per share:
Basic		$	(3.56	)		$	1.29
Diluted		$	(3.56	)		$	1.26
Weighted average number of shares used in calculation:
Basic			8,303,434				8,260,468
Diluted			8,303,434				8,428,197
America’s Car-Mart
Consolidated Results of Operations
(Amounts in thousands, except per share data)
													As a % of Sales
		Twelve Months Ended											Twelve Months Ended
		April 30,											April 30,
			2026				2025			% Change			2026			2025
Statements of Operations:
Revenues:
Sales		$	1,027,813			$	1,146,208			(10.3	)	%	100.0		%	100.0	%
Interest income			253,689				244,724			3.7			24.7			21.4
Total			1,281,502				1,390,932			(7.9	)		124.7			121.4
Costs and expenses:
Cost of sales			663,981				726,055			(8.5	)		64.6			63.3
Selling, general and administrative			208,084				188,921			10.1			20.2			16.5
Provision for credit losses			419,230				374,559			11.9			40.8			32.7
Interest expense			74,494				70,650			5.4			7.2			6.2
Impairment expense			11,016				–			–			1.1			–
Loss on extinguishment of debt			4,476				–			–			0.4			–
Depreciation and amortization			8,207				7,647			7.3			0.8			0.7
(Gain) loss on disposal of property and equipment			(5	)			299			(101.7	)		–			–
Total			1,389,483				1,368,131			1.6			135.2			119.4
Income (Loss) before taxes			(107,981	)			22,801						(10.5	)		2.0
Provision (benefit) for income taxes			31,130				4,869						3.0			0.4
Net income (loss)		$	(139,111	)		$	17,932						(13.5	)		1.6
Dividends on subsidiary preferred stock			(40	)			(40	)
Net income (loss) attributable to common shareholders		$	(139,151	)		$	17,892
Earnings (Loss) per share:
Basic		$	(16.79	)		$	2.38
Diluted		$	(16.79	)		$	2.33

America’s Car-Mart
Condensed Consolidated Balance Sheet and Other Data
(Amounts in thousands, except per share data)
		April 30,				April 30,
			2026				2025
Cash and cash equivalents		$	46,962			$	9,808
Restricted cash from collections on auto finance receivables		$	84,684			$	114,729
Finance receivables, net		$	1,079,167			$	1,180,673
Inventory		$	54,074			$	112,229
Total assets		$	1,416,840			$	1,606,474
Senior Secured Notes Payable, net		$	263,681			$	–
Revolving lines of credit, net		$	–			$	204,769
Non-recourse notes payable, net		$	458,685			$	572,010
Treasury stock		$	298,517			$	298,220
Total equity		$	445,656			$	569,522
Shares outstanding			8,305,520				8,263,280
Book value per outstanding share		$	53.71			$	68.97
Allowance for credit losses			(329,901	)			(323,100	)
Allowance as % of principal balance net of deferred revenue			25.15	%			23.25	%
Changes in allowance for credit losses:
		Twelve Months Ended
		April 30,
			2026				2025
Balance at beginning of period		$	323,100			$	331,260
Provision for credit losses			419,230				374,559
Charge-offs, net of collateral recovered			(412,429	)			(382,719	)
Balance at end of period		$	329,901			$	323,100

America’s Car-Mart
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
		Twelve Months Ended
		April 30,
			2026				2025
Operating activities:
Net loss		$	(139,111	)		$	17,932
Provision for credit losses			419,230				374,559
Losses on claims for accident protection plan			36,276				34,525
Loss on extinguishment of debt			2,726				–
Depreciation and amortization			8,207				7,647
Finance receivable originations			(952,451	)			(1,075,080	)
Finance receivable collections			477,730				469,379
Inventory			180,287				114,573
Deferred accident protection plan revenue			(6,518	)			(378	)
Deferred service contract revenue			(10,313	)			(7,158	)
Income taxes, net			(4,975	)			4,409
Deferred income taxes			27,061				–
Impairment of assets			11,016
Other			15,794				10,828
Net cash provided by (used in) operating activities			64,959				(48,764	)
Investing activities:
Purchase of investments			–				(7,527	)
Purchase of property and equipment and other			(1,810	)			(3,890	)
Proceeds from sale of property and equipment			289				42
Net cash used in investing activities			(1,521	)			(11,375	)
Financing activities:
Issuance of common stock			218				74,106
Purchase of common stock			(297	)			(434	)
Dividend payments			(40	)			(40	)
Change in cash overdrafts			(1,289	)			466
Debt issuance costs			(20,252	)			(9,006	)
Non-recourse notes payable, net			(113,821	)			18,558
Revolving line of credit, net			(207,098	)			6,579
Loss on extinguishment of debt			(1,750	)			–
Issuance of senior secured notes payable			288,000				–
Net cash provided by (used in) financing activities			(56,329	)			90,229
Increase in cash, cash equivalents, and restricted cash		$	7,109			$	30,090

America’s Car-Mart
Reconciliation of Non-GAAP Financial Measures
(Amounts in thousands)
Calculation of Adjusted SG&A as Percentage of Sales:
		Three Months Ended				Three Months Ended
		April 30,				April 30,
			2026				2025
Sales			242,637				309,702
Selling, general and administrative			47,565				48,343
Restructuring-related charges(1)			3,961				–
Adjusted selling, general and administrative			43,604				48,343
Adjusted SG&A as a percentage of sales			18.0	%			15.6	%
America’s Car-Mart
Reconciliation of Non-GAAP Financial Measures
(Amounts in thousands)
Calculation of Adjusted Loss Per Share:
		Three Months Ended				Twelve Months Ended
		April 30,				April 30,
			2026				2026
Net loss attributable to common shareholders (A)		$	(29,575	)		$	(139,151	)
Loss on extinguishment of debt adjustment(1)			–				4,476
Credit loss impact of allowance percentage adjustment			24,927				54,932
Impairment of assets impacted by lot closures and non-core adjustments(1)			6,382				11,016
Restructuring-related charges(1)			3,961				3,961
Pre-tax impact of adjustments (B)			35,270				74,385
Tax effect of adjustment [effective tax rate of (28.83)%] (C)			(10,168	)			(21,445	)
Tax impact of deferred tax asset valuation allowance (D)			8,444				55,454
Post-tax impact of adjustments (B+C+D)			33,546				108,394
Adjusted net loss attributable to common shareholders (A+(B+C+D))			3,971				(30,757	)
Weighted average shares outstanding			8,303				8,289
Adjusted loss per share		$	0.48			$	(3.71	)
Diluted earnings (loss) per share (GAAP)(2)		$	(3.56	)		$	(16.79	)
Diluted earnings (loss) per share impact of adjustments		$	(4.04	)		$	(13.08	)
(1) The Company recorded certain one-time items in each quarter that did not recur in the other period; as a result, the non-GAAP adjustments reflected in each reconciliation may differ between period.
(2) Diluted earnings (loss) per share for the current quarter was the same as basic earnings (loss) per share because the net loss makes potential common stock equivalents anti-dilutive.

America’s Car-Mart
Reconciliation of Non-GAAP Financial Measures
(Amounts in thousands)
Calculation of Debt, Net of Total Cash, to Finance Receivables:
		April 30, 2026				April 30, 2025
Debt:
Senior Secured Notes Payable, net		$	263,681			$	–
Revolving lines of credit, net			–				204,769
Notes payable, net			458,685				572,010
Total debt		$	722,366			$	776,779
Cash:
Cash and cash equivalents		$	46,962			$	9,808
Restricted cash			84,684				114,729
Total cash, cash equivalents, and restricted cash		$	131,646			$	124,537
Debt, net of total cash		$	590,720			$	652,242
Principal balance of finance receivables		$	1,413,059			$	1,509,155
Ratio of debt to finance receivables			51.1	%			51.5	%
Ratio of debt, net of total cash, to finance receivables			41.8	%			43.2	%

An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b6126a8-73d1-4d31-b313-55bae12bee31

WILMINGTON, N.C., July 14, 2026 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), the platform for agentic AI banking, today announced that ConnectOne Bank is actively deploying nCino’s embedded AI capabilities across its commercial lending operations. Through a combination of nCino Banking Advisor capabilities now live in production and two custom AI agents built on the nCino Agentic Operating System (AOS), ConnectOne is expanding what its bankers can do and laying the foundation for a new level of operational performance.

“When we adopted nCino, we needed a tool that could strengthen our efficient operating model as we scaled, while supporting our speed to market,” said Frank Sorrentino III, Chairman and CEO at ConnectOne Bank. “In this next chapter, we are working with nCino to reimagine how our teams work. By leveraging nCino’s investments in AI, we can remove friction & administrative burden from our workflows, and double down on ConnectOne’s competitive advantage – our ability to serve our clients at the pace of their business.”

Early Results

Banking Advisor’s Knowledge Base capability is live in the nCino Commercial Banking Solution at the Bank, and the results are already clear. Document search, a task that previously took bankers 20 minutes, now takes as little as 30 seconds, a 97.5% reduction in time spent searching credit policy and job aid documentation. Adoption has followed, with active users growing 41% in just 10 weeks.

The AOS enables financial institutions to deploy nCino’s native Banking Advisor capabilities out of the box, then build on top of them using their own workflows, data and institutional knowledge, all governed within the same trust infrastructure that underlies nCino’s own Digital Partners, role-based agents, ensuring every AI-assisted action is auditable, explainable and under the institution’s control.

ConnectOne has started with two agents targeting the high-friction, time-consuming tasks that have long defined commercial lending, comprising 16 unique skills with additional capabilities rolling out over the coming months. One agent, which uses Document Intelligence to update individual and business relationships, has already reduced task time by 60%.

nCino’s forward deployed engineering team worked alongside ConnectOne Bank team members to design, build and refine the agent suite directly within the institution’s environment, compressing what would traditionally be a multi-year transformation into an active, iterative deployment measured in weeks.

Building Toward 50%

At nSight, nCino’s annual industry conference, Sorrentino shared how the deployment fits into ConnectOne’s broader ambition: “We are one of the most efficient banks in the country. I believe with the things we’re working on today together with nCino, we are going to be able to make every single one of our frontline people 50 percent more efficient. Fifty percent means our bankers will work a thousand hours less on things that don’t matter and a thousand hours more on the things that do.”

“Frank had the same questions about AI every banking leader has right now; the same board conversations, the same concerns,” said Sean Desmond, CEO at nCino. “The difference is he made a choice to focus on outcomes over checking a box. And the results speak to what that looks like when you build the right foundation and actually commit to it. Frank and his team have turned AI into a measurable operational advantage across the entire lending lifecycle, and the work they’re doing on the AOS puts them ahead of where most of the industry is even trying to get to.”

About ConnectOne Bancorp, Inc.

ConnectOne Bancorp, Inc., is a modern financial services company that operates, through its subsidiary, ConnectOne Bank, and the Bank’s fintech subsidiary, BoeFly, Inc. ConnectOne Bank is a high-performing commercial bank offering a full suite of banking & lending products and services that focus on small to middle-market businesses. BoeFly, Inc. is a fintech marketplace that connects borrowers in the franchise space with funding solutions through a network of partner banks. ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol “CNOB,” and information about ConnectOne may be found at https://www.connectonebank.com.

About nCino

nCino (NASDAQ: NCNO) is the platform for agentic AI banking. With over 2,700 customers worldwide — including community banks, credit unions, independent mortgage banks, and the largest financial entities globally — nCino offers a trusted, agentic platform purpose-built for financial services and regulated industries. By deploying AI agents alongside human teams, nCino’s dual workforce enables institutions to eliminate inefficiencies, sharpen decision-making and deliver better outcomes for the customers they serve. For more information, visit www.ncino.com.

Media Contact

Riley Keyzer

[email protected]

Forward-Looking Statements:

This press release contains forward-looking statements about nCino’s financial and operating results, which include statements regarding nCino’s future performance, outlook, guidance, the benefits from the use of nCino’s solutions, our strategies, and general business conditions. Forward-looking statements generally include actions, events, results, strategies and expectations and are often identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions and the negatives thereof. Any forward-looking statements contained in this press release are based upon nCino’s historical performance and its current plans, estimates, and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent nCino’s expectations as of the date of this press release. Subsequent events may cause these expectations to change and, except as may be required by law, nCino does not undertake any obligation to update or revise these forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially including, but not limited to risks associated with (i) adverse changes in the financial services industry, including as a result of customer consolidation or bank failures; (ii) adverse changes in economic, regulatory, or market conditions, including as a direct or indirect consequence of higher interest rates; (iii) risks associated with acquisitions we undertake, (iv) breaches in our security measures or unauthorized access to our customers’ or their clients’ data; (v) the accuracy of management’s assumptions and estimates; (vi) our ability to attract new customers and succeed in having current customers expand their use of our solution, including in connection with our migration to an asset-based pricing model; (vii) competitive factors, including pricing pressures and migration to asset-based pricing, consolidation among competitors, entry of new competitors, the launch of new products and marketing initiatives by our competitors, and difficulty securing rights to access or integrate with third party products or data used by our customers; (viii) the rate of adoption of our newer solutions and the results of our efforts to sustain or expand the use and adoption of our more established solutions; (ix) fluctuation of our results of operations, which may make period-to-period comparisons less meaningful; (x) our ability to manage our growth effectively including expanding outside of the United States; (xi) adverse changes in our relationship with Salesforce; (xii) our ability to successfully acquire new companies and/or integrate acquisitions into our existing organization; (xiii) the loss of one or more customers, particularly any of our larger customers, or a reduction in the number of users our customers purchase access and use rights for; (xiv) system unavailability, system performance problems, or loss of data due to disruptions or other problems with our computing infrastructure or the infrastructure we rely on that is operated by third parties; (xv) our ability to maintain our corporate culture and attract and retain highly skilled employees; and (xvi) the outcome and impact of legal proceedings and related fees and expenses.